

Kimberly-Clark Announces Second Quarter 2023 Results

Net sales up 1 percent, organic sales grew 5 percent Revenue Growth Management program and productivity drove continued margin recovery Company raises 2023 outlook

DALLAS, July 25, 2023 - Kimberly-Clark Corporation (NYSE: KMB) today reported second quarter 2023 results. Comparisons are made versus the prior year period, unless otherwise noted.

"We delivered another quarter of strong organic sales growth and gross margin expansion." said Chairman and CEO Mike Hsu. "Our growth strategy is working, and given the strength of our first-half results, we're raising our full-year outlook."

Hsu added, "Continued improvement in gross margin positions us well to invest in superior brand value propositions, including innovation and digital leadership, which will help grow our market shares over time and deliver balanced and sustainable growth for long-term shareholder value."

Quarter Highlights

- Delivered net sales of \$5.1 billion, up 1 percent, with organic sales growth of 5 percent.
- Gross margin was 33.7 percent, up 350 basis points; adjusted gross margin was 34.0 percent, up 380 basis
 points versus the prior year, driven by favorable net revenue realization and productivity, offsetting
 inflation.
- Diluted earnings per share were \$0.30, primarily driven by \$1.36 per share in non-cash charges for the impairment of intangible assets; on an adjusted basis, earnings per share were \$1.65.
- Raised 2023 outlook for organic growth to 3% 5%, and for adjusted earnings per share growth of 10% 14%, with adjusted operating margin up 150 basis points at the midpoint versus last year.

Strategic Highlights

- Completed the sale of its Brazil tissue assets in June.
- Launched Huggies' new marketing campaign, *Baby Butts*, celebrating Huggies' unique design protection for babies on the move.
- Received top honors at the Cannes Lion festival for two brand campaigns in Latin America: The Story of Lea Campos by Intimus, which honors one of the first female football referees in Brazil and #NormalicemosLoNormal by Kotex, which fights menstrual stigma.
- Published Global 2022 Sustainability Report, which highlights the company's progress toward its 2030 ambitions, with the goal of improving the lives of 1 billion people in underserved and vulnerable

- communities while driving product innovation, human capital initiatives and reducing its environmental footprint.
- Recognized in Australia as one of the 2023 Most Sustainable Companies for the successful launch of The Nappy Loop, the first recycling program of its kind.
- Recognized by U.S. News and World Report for being one of the Best Places to Work in the U.S.

Second Quarter 2023 Results

Second-quarter sales of \$5.1 billion increased 1 percent, with organic sales up 5 percent, driven by a 9 percent increase in price and favorable product mix from ongoing revenue growth management programs, offset by a 3 percent decrease in volume. Changes in foreign currency exchange rates decreased sales by approximately 4 percent.

In North America, organic sales increased 6 percent over last year, including increases of 1 percent in Personal Care, 7 percent in Consumer Tissue and 17 percent in K-C Professional.

Outside North America, organic sales were up 6 percent in developing and emerging (D&E) markets and 4 percent in developed markets (Australia, South Korea and Western/Central Europe).

Gross margin improved by 350 bps to 33.7 percent and adjusted gross margin improved by 380 basis points to 34.0 percent, with higher net revenue realization and cost savings offsetting higher input costs of \$30 million.

Second-quarter operating profit was \$113 million compared to \$621 million last year, resulting in an operating margin of 2.2 percent. Higher gross margin and the net benefit related to the sale of the Brazil tissue and KC-Professional business were offset by non-cash impairment charges on intangible assets primarily related to the company's Indonesia business, and higher marketing, research and general expenses.

On an adjusted basis, operating profit increased by 17 percent, driven by higher gross profit including \$80 million in FORCE (Focus on Reducing Costs Everywhere) savings, offset by planned marketing, research and general expenses. Inflation increased input costs by \$30 million this quarter. Unfavorable currency effects impacted operating profit by \$100 million during the quarter. Adjusted operating margin of 14.2 percent increased 190 basis points over last year.

Net interest expense was \$67 million, in line with prior year.

Second-quarter effective tax rate was driven by a net benefit from income taxes of \$32 million. On an adjusted basis, the effective rate in the second quarter was 20.5 percent, below 22.0 percent prior year, due to benefits of certain tax planning initiatives.

Net income of equity companies was \$50 million compared to \$29 million last year driven by Kimberly-Clark de Mexico.

Diluted EPS decreased 77 percent to \$0.30 on a reported basis, largely driven by non-cash charges related to impairment of intangible assets. On an adjusted basis, EPS increased 23 percent to \$1.65, driven primarily by the

17 percent increase in adjusted operating profit, in addition to gains in equity income and lower income taxes than the same period last year.

Year-To-Date Results

For the first six months of the year, sales of \$10.3 billion increased 2 percent, with organic sales up 5 percent, driven by a 10 percent increase in price and favorable product mix from ongoing revenue growth management programs offset by a 4 percent decrease in volume. Changes in foreign currency exchange rates decreased sales by approximately 4 percent.

Gross margin improved by 350 basis points to 33.5 percent, and adjusted gross margin improved by 360 basis points to 33.6 percent with higher net revenue realization and cost savings offsetting higher input costs of \$190 million.

Year-to-date operating profit was \$900 million in 2023 and \$1.3 billion in 2022. Results included non-cash impairment charges on intangible assets primarily related to the company's business in Indonesia, higher marketing, research and general expenses, offset by the net benefit from the Brazil divestiture in the second quarter 2023.

Year-to-date adjusted operating profit was \$1.5 billion in 2023 and \$1.3 billion in 2022. The increase in organic sales and FORCE savings was partially offset by higher input costs, marketing, research and general expenses, and unfavorable impact from foreign currency.

Through the last six months, diluted earnings per share were \$1.97 in 2023 compared to \$2.84 last year. Year-to-date adjusted earnings per share were \$3.32 compared to \$2.69 last year.

Business Segment Net Sales Results

Q2 change vs year ago (%)	Volume	Price	Mix/Other	Exited Business ^(a)	Currency	Total ^(b)	Organic ^(c)
Personal Care	(3)	6	1	_	(5)	(1)	4
North America	(3)	3		_	(1)	_	1
D&E Markets	(3)	10	2	_	(11)	(2)	9
Developed Markets	(6)	8	1		(6)	(2)	4
Consumer Tissue	(4)	8	_	(1)	(2)	1	4
North America	2	6	_	_	_	7	7
D&E Markets	(11)	9	_	(5)	(4)	(11)	(1)
Developed Markets	(9)	10	_	_	(3)	(2)	1
KC Professional	(3)	14	2	_	(2)	11	13
North America	3	14	1	_	(1)	16	17
D&E Markets	(7)	10	2	_	(7)	(1)	6
Developed Markets	(14)	18	4	_	(3)	6	9
Consolidated	(3)	8	1	_	(4)	1	5
				Acquisition/ Exited		- (b)	(o
YTD change vs year ago (%)	Volume	Price	Mix/Other	Business ^(a)	Currency	Total ^(b)	Organic ^(c)
Personal Care	(4)	7	1	_	(5)	(1)	3
North America	(2)	3	_	1	(1)	1	1
D&E Markets	(7)	10	2	_	(9)	(3)	6
Developed Markets	(5)	8	1	_	(6)	(2)	4
Consumar Tissua	(4)	0		(1)	(2)	2	5

YTD change vs year ago (%)	Volume	Price	Mix/Other	Business ^(a)	Currency	Total ^(b)	Organic ^(c)
Personal Care	(4)	7	1	_	(5)	(1)	3
North America	(2)	3	_	1	(1)	1	1
D&E Markets	(7)	10	2	_	(9)	(3)	6
Developed Markets	(5)	8	1	_	(6)	(2)	4
Consumer Tissue	(4)	9	_	(1)	(2)	3	5
North America	(1)	7		_		6	6
D&E Markets	(10)	11		(3)	(4)	(5)	2
Developed Markets	(6)	14	_	_	(5)	2	7
KC Professional	(5)	15	1	_	(3)	10	12
North America	_	15	_	_	(1)	14	15
D&E Markets	(6)	10	2	_	(6)	_	6
Developed Markets	(15)	22	4	_	(5)	6	11
Consolidated	(4)	9	1	_	(4)	2	5

⁽a) Impact of the acquisition of Thinx Inc. and sale of Brazil tissue and K-C Professional business.

⁽b) Total may not equal the sum of volume, net price, mix/other, acquisition and currency due to rounding and excludes intergeographic sales.
(c) Combined impact of changes in volume, net price and mix/other.

Personal Care Segment

Personal Care sales of \$2.7 billion decreased 1 percent, while organic sales increased 4 percent, driven by price and mix, partially offset by lower volume. Successful revenue growth management and commercial execution contributed to favorable trends in net revenue realization.

Second-quarter operating profit of \$472 million increased 1 percent, with organic growth and cost savings partially offset by input-cost inflation, higher marketing, research and general expenses, and an unfavorable impact from foreign currency.

Consumer Tissue Segment

Consumer Tissue sales of \$1.5 billion increased 1 percent, including organic growth of 4 percent, with gains from price partially offset by volume. Organic growth of 7 percent in North America led the increase, with gains in both price and volume. Successful revenue growth management and improving service levels contributed to top-line growth.

Second-quarter operating profit of \$200 million increased 12 percent, with organic growth and cost savings partially offset by input-cost inflation, higher other manufacturing costs and higher marketing, research and general expenses.

K-C Professional (KCP) Segment

KCP sales of \$887 million increased 11 percent, including organic growth of 13 percent, driven by price and mix partially offset by volume. The segment increased across key categories and regions, led by North America which had gains in both revenue growth management and volumes.

Second-quarter operating profit of \$187 million increased 120 percent, driven by continued focus on profitable growth and cost discipline.

Cash Flow and Balance Sheet

Year-to-date cash provided by operations was \$1.4 billion compared to \$944 million last year. Year-to-date capital spending was \$389 million compared to \$470 million last year. The company completed share repurchases of 485 thousand shares at a cost of \$65 million during the first half of the year. Total debt was \$8.1 billion as of June 30, 2023 compared to \$8.4 billion at the end of 2022.

2023 OutlookThe company updated its full year expectations for 2023 as summarized below.

Metric	Previous	Current
Organic sales	2% - 4%	3% - 5%
FX impact ^(a) on net sales	(2)%	(2)%
Acquisition/Divestiture impact on net sales	-	~(1)%
Net sales	0% - 2%	0% - 2%
Input cost impact on operating profit (\$ million)	\$(100) - \$(200)	~\$(100)
Operating margin	up 130 bps	up 150 bps
FX impact ^(b) on operating profit (\$ million)	\$(300) - \$(400)	\$(300) - \$(400)
Effective tax rate	23% - 25%	23% - 25%
Income from equity companies	up vs. prior year	up vs. prior year
Adjusted EPS vs. last year	6% - 10%	10% - 14%
Share repurchases (\$ million)	\$100 - \$150	\$100 - \$150

⁽a) Currency translation only

This outlook reflects assumptions subject to change given the macro environment and does not include the impact of impairment charges, net benefit from sale of Brazil tissue and professional business and pension settlements.

Supplemental Materials and Live Webcast

Supplemental materials will be available at 7:00 a.m. Central Time in the Investor Relations section of www.kimberly-clark.com. The company will host a live earnings webcast with investors and analysts on July 25, 2023 at 7:30 a.m. Central Time.

About Kimberly-Clark

Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 80 countries. We use sustainable practices that support a healthy planet, build strong communities, and ensure our business thrives for decades to come. We are proud to be recognized as one of the World's Most Ethical Companies^(R) by Ethisphere for the fifth year in a row. To keep up with the latest news and to learn more about the company's 150-year history of innovation, visit kimberly-clark.com.

Copies of Kimberly-Clark's Annual Report to Stockholders and its proxy statements and other SEC filings, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, are made available free of charge on the company's website on the same day they are filed with the SEC. To view these filings, visit the Investors section of the company's website.

⁽b) Currency transaction and translation impacts

Forward Looking Statements

Certain matters contained in this news release concerning the outlook, anticipated financial and operating results, raw material, energy and other input costs, anticipated currency rates and exchange risks, including in Argentina and Turkey, net income from equity companies, sources and uses of cash, the effective tax rate, the anticipated cost savings from the company's FORCE program, growth initiatives, product innovations, contingencies and anticipated transactions of the company constitute forward-looking statements and are based upon management's expectations and beliefs concerning future events impacting the company. In addition, many factors outside our control, including the war in Ukraine (including the related responses of consumers, customers and suppliers as well as sanctions issued by the U.S., the European Union, Russia or other countries), pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, fluctuations in foreign currency exchange rates, prices and availability of our raw materials, supply chain disruptions, disruptions in the capital and credit markets, counterparty defaults (including customers, suppliers and financial institutions with which we do business), failure to realize the expected benefits or synergies from our acquisition and disposition activity, impairment of goodwill and intangible assets and our projections of operating results and other factors that may affect our impairment testing, changes in customer preferences, severe weather conditions, government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, our ability to maintain key customer relationships, as well as general economic and political conditions globally and in the markets in which we do business, could affect the realization of these estimates.

There can be no assurance that these future events will occur as anticipated or that the company's results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. For a description of certain factors that could cause the company's future results to differ from those expressed in any such forward-looking statements, see Item 1A entitled "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2022.

Non-GAAP Financial Measures

This news release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:

- Adjusted earnings and earnings per share
- Adjusted gross and operating profit
- Adjusted effective tax rate

These non-GAAP financial measures exclude the following items for the relevant time periods as indicated in the accompanying non-GAAP reconciliation tables:

• Sale of Brazil tissue and K-C Professional business. In the second quarter of 2023, we recognized a net benefit related to the sale of our Brazil tissue and K-C Professional business.

- Impairment of intangible assets. In the second quarter of 2023, we recognized non-cash charges related to the impairment of certain intangible assets related to Softex Indonesia and Thinx.
- Pension settlements. In the second quarter of 2022 and 2023, we recognized pension settlement charges
 related to lump-sum distributions from pension plan assets exceeding the total of annual service and
 interest costs resulting in a recognition of deferred actuarial losses.
- Acquisition of controlling interest in Thinx. In the first quarter of 2022, the company completed the
 acquisition of a majority and controlling share of Thinx. As a result of this transaction, a net benefit was
 recognized primarily due to the nonrecurring, non-cash gain recognized related to the remeasurement of
 the carrying value of previously held equity investment to fair value partially offset by transaction and
 integration costs.

The company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the company's Board of Directors use adjusted earnings, adjusted earnings per share and adjusted gross and operating profit to (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations. Additionally, the Management Development and Compensation Committee of the company's Board of Directors has used certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the company's adjusted earnings per share.

This news release includes information regarding organic sales growth, which describes the impact of changes in volume, net selling prices and product mix on net sales. Changes in foreign currency exchange rates, acquisitions and exited businesses also impact the year-over-year change in net sales.

KIMBERLY-CLARK CORPORATION CONSOLIDATED INCOME STATEMENTS

(Millions, except per share amounts)

	Thr	Three Months Ended June 30			
		2023		2022	Change
Net Sales	\$	5,134	\$	5,063	+1%
Cost of products sold		3,403		3,534	-4%
Gross Profit		1,731		1,529	+13%
Marketing, research and general expenses		1,015		906	+12%
Impairment of intangible assets		658			N.M.
Other (income) and expense, net		(55)		2	N.M.
Operating Profit		113		621	-82%
Nonoperating expense		(42)		(27)	+56%
Interest income		9		1	+800%
Interest expense		(76)		(68)	+12%
Income Before Income Taxes and Equity Interests		4		527	-99%
(Provision for) benefit from income taxes		32		(115)	N.M.
Income Before Equity Interests		36		412	-91%
Share of net income of equity companies		50		29	+72%
Net Income		86		441	-80%
Net (income) loss attributable to noncontrolling interests		16		(4)	N.M.
Net Income Attributable to Kimberly-Clark Corporation	\$	102	\$	437	-77%
Per Share Basis					
Net Income Attributable to Kimberly-Clark Corporation					
Basic	\$	0.30	\$	1.30	-77%
Diluted	\$	0.30	\$	1.29	-77%
Cash Dividends Declared	\$	1.18	\$	1.16	+2%
Common Shares Outstanding		Jun	e 30		
		2023		2022	
Outstanding shares as of		338.2		337.6	
Average diluted shares for three months ended		338.9		338.3	

KIMBERLY-CLARK CORPORATION CONSOLIDATED INCOME STATEMENTS

(Millions, except per share amounts)

	S	Six Months Ended June 30			
		2023		2022	Change
Net Sales	\$	10,329	\$	10,158	+2%
Cost of products sold		6,872		7,109	-3%
Gross Profit		3,457		3,049	+13%
Marketing, research and general expenses		1,939		1,792	+8%
Impairment of intangible assets		658			N.M.
Other (income) and expense, net		(40)		(57)	-30%
Operating Profit		900		1,314	-32%
Nonoperating expense		(58)		(31)	+87%
Interest income		16		3	+433%
Interest expense		(149)		(133)	+12%
Income Before Income Taxes and Equity Interests		709		1,153	-39%
Provision for income taxes		(141)		(229)	-38%
Income Before Equity Interests		568		924	-39%
Share of net income of equity companies		93		52	+79%
Net Income		661		976	-32%
Net (income) loss attributable to noncontrolling interests		7		(16)	N.M.
Net Income Attributable to Kimberly-Clark Corporation	\$	668	\$	960	-30%
Per Share Basis					
Net Income Attributable to Kimberly-Clark Corporation					
Basic	\$	1.98	\$	2.85	-31%
Diluted	\$	1.97	\$	2.84	-31%
Cash Dividends Declared	\$	2.36	\$	2.32	+2%
Common Shares Outstanding		Jun	e 30		
		2023		2022	
Average diluted shares for six months ended		338.7		338.3	

KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS

(Millions, except per share amounts)

Three Months Ended June 30, 2023

	As Reported		Sale of Brazil Tissue and K-C Professional Business		Impairment of Intangible Assets	Pension Settlements	As Adjusted Non-GAAP
Cost of products sold	\$	3,403	\$	15	<u> </u>	s —	\$ 3,388
Gross Profit		1,731		(15)	_	_	1,746
Marketing, research and general expenses		1,015		15	_	_	1,000
Impairment of intangible assets		658		_	658	_	_
Other (income) and expense, net		(55)		(74)	_	_	19
Operating Profit		113		44	(658)	_	727
Nonoperating expense		(42)		_	_	(27)	(15)
(Provision for) benefit from income taxes		32		(18)	175	7	(132)
Effective tax rate		N.M.			_	_	20.5%
Net (income) loss attributable to noncontrolling interests		16		_	20	_	(4)
Net Income Attributable to Kimberly-Clark Corporation		102		26	(463)	(20)	559
Diluted Earnings per Share ^(a)		0.30		0.08	(1.36)	(0.06)	1.65

Three	Months	Ended Jur	e 30, 2022
111166	VIUILLIS	ranaca aur	10 30. 4044

	R	As eported	S	Pension ettlements	As djusted n-GAAP
Nonoperating expense	\$	(27)	\$	(24)	\$ (3)
Provision for income taxes		(115)		6	(121)
Effective tax rate		21.8%		_	22.0%
Net Income Attributable to Kimberly-Clark Corporation		437		(18)	455
Diluted Earnings per Share ^(a)		1.29		(0.05)	1.34

⁽a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.

N.M. - Not Meaningful

KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS

(Millions, except per share amounts)

Six Months Ended June 30, 2023

		Sale of Brazil Tissue and K-C Impairment of As Professional Intangible Pension Reported Business Assets Settlements			As Adjusted Non-GAAP					
Cost of products sold	\$ 6,8	72	\$	15	\$		\$	_	\$	6,857
Gross Profit	3,45	57		(15)				_		3,472
Marketing, research and general expenses	1,93	39		15				_		1,924
Impairment of intangible assets	6:	58		_		658		_		_
Other (income) and expense, net	(4	40)		(74)						34
Operating Profit	90	00		44		(658)		_		1,514
Nonoperating expense	(:	58)		_				(27)		(31)
Provision for income taxes	(14	41)		(18)		175		7		(305)
Effective tax rate	19	.9%		_				_		22.6%
Net (income) loss attributable to noncontrolling interests		7		_		20		_		(13)
Net Income Attributable to Kimberly-Clark Corporation	60	58		26		(463)		(20)		1,125
Diluted Earnings per Share ^(a)	1.9	97		0.08		(1.36)	(0	0.06)		3.32

	Six Months Ended June 30, 2022								
	As Reported		Acquisition of Controlling Interest in Thinx		Pension Settlements			As djusted on-GAAP	
Marketing, research and general expenses	\$	1,792	\$	21	\$		\$	1,771	
Other (income) and expense, net		(57)		(85)		_		28	
Operating Profit		1,314		64		_		1,250	
Nonoperating expense		(31)				(24)		(7)	
Provision for income taxes		(229)		4		6		(239)	
Effective tax rate		19.9%		_				21.5%	
Net Income Attributable to Kimberly-Clark Corporation		960		68		(18)		910	
Diluted Earnings per Share ^(a)		2.84		0.20		(0.05)		2.69	

⁽a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. The company compensates for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures.

KIMBERLY-CLARK CORPORATION CONSOLIDATED BALANCE SHEETS (Millions)

	June 30, 2023		December 31, 2022	
ASSETS				
Current Assets				
Cash and cash equivalents	\$	580	\$	427
Accounts receivable, net		2,359		2,280
Inventories		2,128		2,269
Other current assets		677		753
Total Current Assets		5,744		5,729
Property, Plant and Equipment, Net		7,815		7,885
Investments in Equity Companies		299		238
Goodwill		2,086		2,074
Other Intangible Assets, Net		208		851
Other Assets		1,231		1,193
TOTAL ASSETS	\$	17,383	\$	17,970
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities				
Debt payable within one year	\$	188	\$	844
Trade accounts payable		3,713		3,813
Accrued expenses and other current liabilities		2,302		2,289
Dividends payable		395		388
Total Current Liabilities		6,598		7,334
Long-Term Debt		7,947		7,578
Noncurrent Employee Benefits		639		654
Deferred Income Taxes		490		647
Other Liabilities		848		799
Redeemable Common and Preferred Securities of Subsidiaries		210		258
Stockholders' Equity				
Kimberly-Clark Corporation		500		547
Noncontrolling Interests		151		153
Total Stockholders' Equity		651		700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	17,383	\$	17,970

KIMBERLY-CLARK CORPORATION CONSOLIDATED CASH FLOW STATEMENTS (Millions)

Operating Activities 5 661 9 70 Net income \$ 661 9 70 Depreciation and amortization 377 380 Asset impairments 676 — Gain on previously held equity investment in Thinx — 685 Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions 71 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (10) Other 10 (30) (34) Postretirement benefits 26 (10) (30) Actash Provided by Operations 140 (70) (30) Postretirement benefits 26 (47) (45) Acquisition of business, net of cash acquired 21 (47) (45) Proceeds from asset and business dispositions 218 (47) (45) Other 26		Six Months Er	nded June 30	
Net income \$ 661 \$ 976 Depreciation and amortization 377 380 Asset impairments 676 — Gain on previously held equity investment in Thinx — (85) Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (30) Cash Provided by Operations 1400 944 Investing Activities — (40) Capital spending (389) (470) Acquisition of business, net of cash acquired — (40) Proceeds from asset and business dispositions 218 1 Investing Activities 218 1 Cash Used for Investing (70) (775) Change in short-term debt (307) 553 <th></th> <th>2023</th> <th colspan="2">2022</th>		2023	2022	
Depreciation and amortization 377 380 Asset impairments 676 — Gain on previously held equity investment in Thinx — (85) Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (36) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities (70) (3) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits 388 (300) Maurities of time deposits (389) (389) (389) Other 14 (7) (75) (277) <	Operating Activities			
Asset impairments 676 — Gain on previously held equity investment in Thinx — (85) Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits (7 (3) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities (77) (3) Capital spending (87) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits 3(38) (300) Maturities of time deposits 470 545 Other (36) (27) Cash Used for Investing (75) (277) Financing Activities (75) (277) </td <td>Net income</td> <td>\$ 661</td> <td>\$ 976</td>	Net income	\$ 661	\$ 976	
Gain on previously held equity investment in Thinx — (85) Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' carnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities	Depreciation and amortization	377	380	
Stock-based compensation 71 68 Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (10) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 2 (470) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits (388) (300) Other 14 (7) Cash Used for Investing (75) (27) Financing Activities (370) (53 Cash dividends paid (790) (775) Change in short-term debt (30) (50)	Asset impairments	676		
Deferred income taxes (238) (35) Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 389 (470) Acquisition of business, net of cash acquired (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 367 - Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 - Debt proceeds from exercise of stock options 96 75 <	Gain on previously held equity investment in Thinx	_	(85)	
Net (gains) losses on asset and business dispositions (71) 13 Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 2 (470) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 357 — Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt proceeds from exercise of stock options 96 75	Stock-based compensation	71	68	
Equity companies' earnings (in excess of) less than dividends paid (60) (21) Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 2 (470) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits (388) (300) Maturities of time deposits (7) (277) Financing Activities (7) (277) Cash Used for Investing (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt proceeds 357 — Debt propayments (350) (300) Proceeds from exercise of stock options 96 75	Deferred income taxes	(238)	(35)	
Operating working capital (35) (348) Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 340 (470) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 3 (75) (277) Formating Activities 3 (75) (277) Formating Activities 3 (75) (277) Formating Activities 3 (79) (75) Cash dividends paid (790) (75) (75) Debt repayments (350) (350) (350) (350) (350) (350)	Net (gains) losses on asset and business dispositions	(71)	13	
Postretirement benefits 26 (1) Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 348 (470) Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 14 (7) Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividen	Equity companies' earnings (in excess of) less than dividends paid	(60)	(21)	
Other (7) (3) Cash Provided by Operations 1,400 944 Investing Activities 94 Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) (277) Cash Used for Investing (75) (275) (277) Financing Activities 7 (75) (275) Cash dividends paid (790) (775) (75) (275) Change in short-term debt (307) 553 -	Operating working capital	(35)	(348)	
Cash Provided by Operations 1,400 944 Investing Activities 2 470 Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 7 (75) (75) Cash dividends paid (790) (775) (75) Change in short-term debt (307) 553 — Debt proceeds 357 — — Debt repayments (350) (300) 96 75 Acquisitions of common stock for the treasury (63) (49) — Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42	Postretirement benefits	26	(1)	
Investing Activities (389) (470) Capital spending — (46) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities (790) (775) Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620)	Other	(7)	(3)	
Capital spending (389) (470) Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities — (790) (775) Change in short-term debt (307) 553 — Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Cha	Cash Provided by Operations	1,400	944	
Acquisition of business, net of cash acquired — (46) Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities (790) (775) Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beg	Investing Activities			
Proceeds from asset and business dispositions 218 1 Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 75 (790) (775) Change in short-term debt (307) 553 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (60) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270 <td>Capital spending</td> <td>(389)</td> <td>(470)</td>	Capital spending	(389)	(470)	
Investments in time deposits (388) (300) Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities	Acquisition of business, net of cash acquired	_	(46)	
Maturities of time deposits 470 545 Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 75 (790) (775) Cash dividends paid (790) (775) 53 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270	Proceeds from asset and business dispositions	218	1	
Other 14 (7) Cash Used for Investing (75) (277) Financing Activities 7 (790) (775) Cash dividends paid (790) (775) (7	Investments in time deposits	(388)	(300)	
Cash Used for Investing (75) (277) Financing Activities (790) (775) Cash dividends paid (307) 553 Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270	Maturities of time deposits	470	545	
Cash Used for Investing (75) (277) Financing Activities Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270	Other	14	(7)	
Financing Activities Cash dividends paid (790) (775) Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270	Cash Used for Investing	(75)		
Change in short-term debt (307) 553 Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270			<u> </u>	
Debt proceeds 357 — Debt repayments (350) (300) Proceeds from exercise of stock options 96 75 Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (48) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period 427 270	Cash dividends paid	(790)	(775)	
Debt repayments(350)(300)Proceeds from exercise of stock options9675Acquisitions of common stock for the treasury(63)(49)Cash paid for redemption of common securities of Thinx(48)—Cash dividends paid to noncontrolling interests(16)(82)Other(31)(42)Cash Used for Financing(1,152)(620)Effect of Exchange Rate Changes on Cash and Cash Equivalents(20)(6)Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Change in short-term debt	(307)	553	
Proceeds from exercise of stock options Acquisitions of common stock for the treasury (63) (49) Cash paid for redemption of common securities of Thinx (28) — Cash dividends paid to noncontrolling interests (16) (82) Other (31) (42) Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents (20) (6) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period	Debt proceeds	357		
Acquisitions of common stock for the treasury Cash paid for redemption of common securities of Thinx (48) Cash dividends paid to noncontrolling interests (16) (82) Other Cash Used for Financing (1,152) (620) Effect of Exchange Rate Changes on Cash and Cash Equivalents Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period (48) —— (82) (620) (620) (620) (620) (620)	Debt repayments	(350)	(300)	
Cash paid for redemption of common securities of Thinx Cash dividends paid to noncontrolling interests Other Cash Used for Financing Cash Used for Financing Effect of Exchange Rate Changes on Cash and Cash Equivalents Change in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning of Period (48) (82) (31) (42) (620) (620) Change in Cash and Cash Equivalents 153 41 Cash and Cash Equivalents - Beginning of Period	Proceeds from exercise of stock options	96	75	
Cash dividends paid to noncontrolling interests(16)(82)Other(31)(42)Cash Used for Financing(1,152)(620)Effect of Exchange Rate Changes on Cash and Cash Equivalents(20)(6)Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Acquisitions of common stock for the treasury	(63)	(49)	
Other(31)(42)Cash Used for Financing(1,152)(620)Effect of Exchange Rate Changes on Cash and Cash Equivalents(20)(6)Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Cash paid for redemption of common securities of Thinx	(48)		
Cash Used for Financing(1,152)(620)Effect of Exchange Rate Changes on Cash and Cash Equivalents(20)(6)Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Cash dividends paid to noncontrolling interests	(16)	(82)	
Effect of Exchange Rate Changes on Cash and Cash Equivalents(20)(6)Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Other	(31)	(42)	
Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Cash Used for Financing	(1,152)	(620)	
Change in Cash and Cash Equivalents15341Cash and Cash Equivalents - Beginning of Period427270	Effect of Exchange Rate Changes on Cash and Cash Equivalents	(20)	(6)	
	Change in Cash and Cash Equivalents	153		
	Cash and Cash Equivalents - Beginning of Period	427	270	
		\$ 580	\$ 311	

KIMBERLY-CLARK CORPORATION SELECTED BUSINESS SEGMENT DATA (Millions)

	T	hree Moi Jun	 		Six Months Ended June 30				
		2023	2022	Change		2023		2022	Change
NET SALES									
Personal Care	\$	2,685	\$ 2,710	-1%	\$	5,389	\$	5,439	-1%
Consumer Tissue		1,549	1,537	+1%		3,183		3,105	+3%
K-C Professional		887	802	+11%		1,734		1,582	+10%
Corporate & Other		13	14	N.M.		23		32	N.M.
TOTAL NET SALES	\$	5,134	\$ 5,063	+1%	\$	10,329	\$	10,158	+2%
OPERATING PROFIT									
Personal Care	\$	472	\$ 466	+1%	\$	959	\$	941	+2%
Consumer Tissue		200	178	+12%		440		349	+26%
K-C Professional		187	85	+120%		346		175	+98%
Corporate & Other ^(a)		(801)	(106)	N.M.		(885)		(208)	N.M.
Other (income) and expense, net ^(a)		(55)	2	N.M.		(40)		(57)	-30%
TOTAL OPERATING PROFIT	\$	113	\$ 621	-82%	\$	900	\$	1,314	-32%

⁽a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including adjustments as indicated in the Non-GAAP Reconciliations.

KIMBERLY-CLARK CORPORATION NON-GAAP RECONCILIATIONS OUTLOOK FOR 2023

ESTIMATED FULL YEAR 2023 DILUTED EARNINGS PER SHARE VS. PRIOR YEAR	Estimated Range			
Adjusted diluted earnings per share vs. prior year	10%	-	14%	
Impact from:				
Sale of Brazil tissue and K-C Professional business	1%	-	1%	
Impairment of intangible assets	(24)%	-	(24)%	
Pension settlements	(2)%	-	(1)%	
Diluted earnings per share vs. prior year	(15)%	-	(10)%	
Pension settlements	(2)%	-	(1)%	

Investor Relations contact: Christina Cheng, KC.InvestorRelations@kcc.com Media Relations contact: David Kellis, media.relations@kcc.com